^
Association details:
| Biomarker: | EGFR T790M |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Gilotrif (afatinib) (EGFR inhibitor, HER2 inhibitor, HER4 inhibitor) + Jakafi (ruxolitinib) (JAK2 inhibitor, JAK1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A phase Ib study of the combination of afatinib and ruxolitinib in EGFR mutant NSCLC with progression on EGFR-TKIs
Excerpt:
As of October 2017, 30 patients participated in the study, of which 20 had T790 M mutations...Objective response rate was 23.3% (no complete response [CR] and 7 partial responses [PR]) and disease control rate was 93.3% (no CR, 7 PR and 21 stable diseases). The median progression-free survival was 4.9 months (95% CI, 2.4-7.5).
DOI:
10.1016/j.lungcan.2019.05.030
Trial ID:
